Do pilocarpine drops help dry mouth in palliative care patients: a protocol for an aggregated series of n-of-1 trials

Jane Nikles, Geoffrey K Mitchell, Janet Hardy, Meera Agar, Hugh Senior, Sue-Ann Carmont, Philip J Schluter, Phillip Good, Rohan Vora, David Currow, Jane Nikles, Geoffrey K Mitchell, Janet Hardy, Meera Agar, Hugh Senior, Sue-Ann Carmont, Philip J Schluter, Phillip Good, Rohan Vora, David Currow

Abstract

Background: It is estimated that 39,000 Australians die from malignant disease yearly. Of these, 60% to 88% of advanced cancer patients suffer xerostomia, the subjective feeling of mouth dryness. Xerostomia has significant physical, social and psychological consequences which compromise function and quality of life. Pilocarpine is one treatment for xerostomia. Most studies have shown some variation in individual response to pilocarpine, in terms of dose used, and timing and extent of response.We will determine a population estimate of the efficacy of pilocarpine drops (6 mg) three times daily compared to placebo in relieving dry mouth in palliative care (PC) patients. A secondary aim is to assess individual patients' response to pilocarpine and provide reports detailing individual response to patients and their treating clinician.

Methods/design: Aggregated n-of-1 trials (3 cycle, double blind, placebo-controlled crossover trials using standardized measures of effect). Individual trials will identify which patients respond to the medication. To produce a population estimate of a treatment effect, the results of all cycles will be aggregated.

Discussion: Managing dry mouth with treatment supported by the best possible evidence will improve functional status of patients, and improve quality of life for patients and carers. Using n-of-1 trials will accelerate the rate of accumulation of high-grade evidence to support clinical therapies used in PC.

Trial registration: Australia and New Zealand Clinical Trial Registry Number: 12610000840088.

Figures

Figure 1
Figure 1
Example of n-of-1 design schema1.

References

    1. Australian Institute of Health & Welfare. Cancer in Australia: an overview, 2006. Canberra: AIHW; 2007.
    1. Feio M, Sapeta P. Xerostomia in PC. Acta Medica Portugesa. 2005;18((6):459–465. Epub 2006 Mar 6.
    1. Mercadante S, Villari P, Ferrera P, Casuccio A. Opioid-induced or pain relief-reduced symptoms in advanced cancer patients? Eur J Pain. 2006;10(2):153–159. doi: 10.1016/j.ejpain.2005.02.006.
    1. Atkinson JC, Grisius M, Massey W. Salivary hypofunction and xerostomia: diagnosis and treatment. Dent Clin North Am. 2005;49(2):309–326. doi: 10.1016/j.cden.2004.10.002.
    1. Guchelaar HJ, Vermes A, Meerwaldt JH. Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer. 1997;5(4):281–288. doi: 10.1007/s005200050075.
    1. De Conno F, Ripamonti C, Sbanotto A, Ventafridda V. Oral complications in patients with advanced cancer. J Palliat Care. 1989;5(1):7–15. Review.
    1. Tsai JS, Wu CH, Chiu TY, Hu WY, Chen CY. Symptom patterns of advanced cancer patients in a PC unit. Palliat Med. 2006;20(6):617–622. doi: 10.1177/0269216306071065.
    1. Bernardi R, Perin C, Becker FL, Ramos GZ, Gheno GZ, Lopes LR, Pires M, Barros HM. Effect of pilocarpine mouthwash on salivary flow. Braz J Med Biol Res. 2002;35:105–110.
    1. Aframian DJ, Helcer M, Livni D, Robinson SD, Markitziu A, Nadler C. Pilocarpine treatment in a mixed cohort of xerostomic patients. Oral Dis. 2007;13(1):88–92. doi: 10.1111/j.1601-0825.2006.01252.x.
    1. LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, Gallagher SC, Muscoplat CC. A multicenter, randomised, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol. 1993;11(6):1124–1131.
    1. Rieke JW, Hafermann MD, Johnson JT, LeVeque FG, Iwamoto R, Steiger BW, Muscoplat C, Gallagher SC. Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomised clinical trials. Int J Radiat Oncol Biol Phys. 1995;31(3):661–669. doi: 10.1016/0360-3016(94)00361-N.
    1. Singhal S, Powles R, Treleaven J, Rattenbury H, Mehta J. Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. Leuk Lymphoma. 1997;24(5–6):539–543.
    1. Papas AS, Sherrer YS, Charney M, Golden HE, Medsger TA Jr, Walsh BT, Trivedi M, Goldlust B, Gallagher SC. Successful treatment of dry mouth and dry eye symptoms in Sjögren's syndrome patients with oral pilocarpine: a randomised, placebo- controlled, dose-adjustment study. J Clin Rheumatol. 2004;10(4):169–177. doi: 10.1097/01.rhu.0000135553.08057.21.
    1. Chitapanarux I, Kamnerdsupaphon P, Tharavichitkul E, Sumitsawan Y, Sittitrai P, Pattarasakulchai T, Lorvidhaya V, Sukthomya V, Pukanhaphan N, Traisatit P. Effect of oral pilocarpine on post-irradiation xerostomia in head and neck cancer patients: a single-center, single-blind clinical trial. J Med Assoc Thai. 2008;91(9):1410–1415.
    1. Davies AN, Shorthose K. Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy. Cochrane Database Syst Rev. 2007;18(3):CD003782.
    1. Davies AN, Daniels C, Pugh R, Sharma K. A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer. Palliat Med. 1998;2:105–111.
    1. Hermet R, Burucia B, Sentilles-Monkam A. The need for evidence-based proof in PC. Eur J Pall Care. 2002;9:104–107.
    1. Nikles J, Mitchell G, Schluter P, Good P, Hardy J, Rowett D, Selby-James T, Vohra S, Currow D. Aggregating single patient (n-of-1) trials in populations where recruitment and retention was difficult: The case of palliative care. J Clin Epi. 2011;64(5):471–480. doi: 10.1016/j.jclinepi.2010.05.009.
    1. Nikles CJ, Glasziou PP, Del Mar CB, Duggan CM, Mitchell G. N of 1 trials. Practical tools for medication management. Aust Fam Physician. 2000;29(11):1108–1112.
    1. Oral pilocarpine: new preparation. Xerostomia after radiation therapy: moderately effective but costly. Prescrire Int. 2002;11(60):99–101.
    1. Kasama T, Shiozawa F, Isozaki T, Matsunawa M, Wakabayashi K, Odai T, Yajima N, Miwa Y, Negishi M, Ide H. Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjogren’s syndrome. Mod Rheumatol. 2008;18:455–459. doi: 10.1007/s10165-008-0078-4.
    1. Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev. 2011;7(12):CD008934.
    1. Thomson WM, Chalmers JM, Spencer AJ, Williams SM. The Xerostomia Inventory: a multi-item approach to measuring dry mouth. Community Dent Health. 1999;16(1):12–17.
    1. National Cancer Institute, US National Institutes of Health. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Publish Date: August 9, 2006. [ ]
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18. doi: 10.1186/1741-7015-8-18.
    1. Sindhu BS, Shechtman O, Tuckey L. Validity, reliability, and responsiveness of a digital version of the visual analog scale. J Hand Ther. 2011;24(4):356–363. doi: 10.1016/j.jht.2011.06.003.
    1. Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC. Performance status across PC settings: agreement between three versions of the Karnofsky Performance Scale. BMC Palliat Care. 2005;4:7. doi: 10.1186/1472-684X-4-7.
    1. Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Bjorner JB. EORTC Quality of Life Group. The development of the EORTC QLQ-C15-PAL: A shortened questionnaire for cancer patients in PC. Eur J Cancer. 2006;42(5):5–64.
    1. Baker SR, Pankhurst CL, Robinson PG. Utility of two oral health-related quality of-life measures in patients with xerostomia. Community Dent Oral Epidemiol. 2006;34:351–362. doi: 10.1111/j.1600-0528.2006.00285.x.
    1. Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004;27:26–35. doi: 10.1016/j.jmpt.2003.11.003.
    1. Thomson WM, Williams SM. Further testing of the xerostomia inventory. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;89(1):46–50. doi: 10.1016/S1079-2104(00)80013-X.
    1. Bland M. An Introduction to Medical Statistics. 3. Oxford: Oxford University Press; 2000.
    1. Zucker DR, Schmid CH, McIntosh MW, D'Agostino RB, Selker HP, Lau J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol. 1997;50(4):401–410. doi: 10.1016/S0895-4356(96)00429-5.
    1. Schluter PJ, Ware RS. Single patient (n-of-1) trials with binary treatment preference. Stat Med. 2005;24(17):2625–2636. doi: 10.1002/sim.2132.
    1. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput. 2000;10(4):325–337. doi: 10.1023/A:1008929526011.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit